Stan Smith Purchases 57,189 Shares of MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Stan Smith purchased 57,189 shares of MAIA Biotechnology stock in a transaction dated Monday, December 22nd. The stock was bought at an average price of $1.22 per share, for a total transaction of $69,770.58. Following the completion of the transaction, the director directly owned 1,421,478 shares in the company, valued at $1,734,203.16. The trade was a 4.19% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Stan Smith also recently made the following trade(s):

• On Friday, December 5th, Stan Smith bought 13,740 shares of MAIA Biotechnology stock. The shares were acquired at an average price of $1.20 per share, with a total value of $16,488.00.
• On Tuesday, November 25th, Stan Smith bought 15,000 shares of MAIA Biotechnology stock. The shares were acquired at an average cost of $0.98 per share, for a total transaction of $14,700.00.
• On Monday, November 24th, Stan Smith purchased 10,000 shares of MAIA Biotechnology stock. The shares were acquired at an average cost of $0.99 per share, with a total value of $9,900.00.
• On Wednesday, October 1st, Stan Smith acquired 19,230 shares of MAIA Biotechnology stock. The shares were bought at an average cost of $1.30 per share, with a total value of $24,999.00.

MAIA Biotechnology Price Performance

NYSEAMERICAN:MAIA opened at $1.48 on Thursday. The company has a market cap of $54.80 million and a P/E ratio of -2.03. The firm’s fifty day moving average price is $1.21 and its two-hundred day moving average price is $1.50. MAIA Biotechnology, Inc. has a one year low of $0.87 and a one year high of $2.74.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last announced its earnings results on Friday, November 7th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.08). As a group, equities research analysts expect that MAIA Biotechnology, Inc. will post -1.3 earnings per share for the current year.

Institutional Trading of MAIA Biotechnology

Several hedge funds have recently added to or reduced their stakes in the company. Centric Wealth Management boosted its stake in MAIA Biotechnology by 740.2% in the 2nd quarter. Centric Wealth Management now owns 573,398 shares of the company’s stock valued at $1,032,000 after purchasing an additional 505,150 shares during the period. Centerpoint Advisory Group acquired a new stake in shares of MAIA Biotechnology during the second quarter worth $28,000. Jane Street Group LLC bought a new stake in shares of MAIA Biotechnology in the second quarter valued at about $52,000. Marshall Wace LLP acquired a new position in shares of MAIA Biotechnology in the second quarter valued at about $29,000. Finally, Geode Capital Management LLC grew its stake in shares of MAIA Biotechnology by 3.6% in the second quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock valued at $400,000 after acquiring an additional 7,746 shares in the last quarter. 5.65% of the stock is owned by institutional investors and hedge funds.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.